Clinical features and treatment of COVID‐19 patients in northeast Chongqing
-
- Suxin Wan
- Pharmaceutical Department of Chongqing Three Gorges Central Hospital Chongqing University Three Gorges Hospital Chongqing China
-
- Yi Xiang
- Pharmaceutical Department of Chongqing Three Gorges Central Hospital Chongqing University Three Gorges Hospital Chongqing China
-
- Wei Fang
- Pharmaceutical Department of Chongqing Three Gorges Central Hospital Chongqing University Three Gorges Hospital Chongqing China
-
- Yu Zheng
- Pharmacy College, Chengdu University of Traditional Chinese Medicine, Key Laboratory of Standardization of Chinese Herbal Medicine, Ministry of Education, Key Laboratory of Systematic Research, Development and Utilization of Chinese Medicine Resources in Sichuan Province, Key Laboratory Breeding Base of Co‐founded by Sichuan Province and Ministry of Science and Technology Chongqing University Three Gorges Hospital Chengdu China
-
- Boqun Li
- Pharmaceutical Department of Chongqing Three Gorges Central Hospital Chongqing University Three Gorges Hospital Chongqing China
-
- Yanjun Hu
- Pharmaceutical Department of Chongqing Three Gorges Central Hospital Chongqing University Three Gorges Hospital Chongqing China
-
- Chunhui Lang
- Pharmaceutical Department of Chongqing Three Gorges Central Hospital Chongqing University Three Gorges Hospital Chongqing China
-
- Daoqiu Huang
- Pharmaceutical Department of Chongqing Three Gorges Central Hospital Chongqing University Three Gorges Hospital Chongqing China
-
- Qiuyan Sun
- Pharmaceutical Department of Chongqing Three Gorges Central Hospital Chongqing University Three Gorges Hospital Chongqing China
-
- Yan Xiong
- Pharmaceutical Department of Chongqing Three Gorges Central Hospital Chongqing University Three Gorges Hospital Chongqing China
-
- Xia Huang
- Pharmaceutical Department of Chongqing Three Gorges Central Hospital Chongqing University Three Gorges Hospital Chongqing China
-
- Jinglong Lv
- Pharmaceutical Department of Chongqing Three Gorges Central Hospital Chongqing University Three Gorges Hospital Chongqing China
-
- Yaling Luo
- Department of Mathematics, College of Medical Information Chongqing Medical University Chongqing China
-
- Li Shen
- Pharmaceutical Department of Chongqing Three Gorges Central Hospital Chongqing University Three Gorges Hospital Chongqing China
-
- Haoran Yang
- Pharmaceutical Department of Chongqing Three Gorges Central Hospital Chongqing University Three Gorges Hospital Chongqing China
-
- Gu Huang
- Pharmaceutical Department of Chongqing Three Gorges Central Hospital Chongqing University Three Gorges Hospital Chongqing China
-
- Ruishan Yang
- Pharmaceutical Department of Chongqing Three Gorges Central Hospital Chongqing University Three Gorges Hospital Chongqing China
Description
<jats:title>Abstract</jats:title><jats:sec><jats:label /><jats:p>The outbreak of the novel coronavirus in China (SARS‐CoV‐2) that began in December 2019 presents a significant and urgent threat to global health. This study was conducted to provide the international community with a deeper understanding of this new infectious disease. Epidemiological, clinical features, laboratory findings, radiological characteristics, treatment, and clinical outcomes of 135 patients in northeast Chongqing were collected and analyzed in this study. A total of 135 hospitalized patients with COVID‐19 were enrolled. The median age was 47 years (interquartile range, 36‐55), and there was no significant gender difference (53.3% men). The majority of patients had contact with people from the Wuhan area. Forty‐three (31.9%) patients had underlying disease, primarily hypertension (13 [9.6%]), diabetes (12 [8.9%]), cardiovascular disease (7 [5.2%]), and malignancy (4 [3.0%]). Common symptoms included fever (120 [88.9%]), cough (102 [76.5%]), and fatigue (44 [32.5%]). Chest computed tomography scans showed bilateral patchy shadows or ground glass opacity in the lungs of all the patients. All patients received antiviral therapy (135 [100%]) (Kaletra and interferon were both used), antibacterial therapy (59 [43.7%]), and corticosteroids (36 [26.7%]). In addition, many patients received traditional Chinese medicine (TCM) (124 [91.8%]). It is suggested that patients should receive Kaletra early and should be treated by a combination of Western and Chinese medicines. Compared to the mild cases, the severe ones had lower lymphocyte counts and higher plasma levels of Pt, APTT, d‐dimer, lactate dehydrogenase, PCT, ALB, C‐reactive protein, and aspartate aminotransferase. This study demonstrates the clinic features and therapies of 135 COVID‐19 patients. Kaletra and TCM played an important role in the treatment of the viral pneumonia. Further studies are required to explore the role of Kaletra and TCM in the treatment of COVID‐19.</jats:p></jats:sec>
Journal
-
- Journal of Medical Virology
-
Journal of Medical Virology 92 (7), 797-806, 2020-04
Wiley
- Tweet
Details 詳細情報について
-
- CRID
- 1363951794418417664
-
- ISSN
- 10969071
- 01466615
-
- Data Source
-
- Crossref